Entera Bio Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, dated June 26, 2020, reports the results of Entera Bio Ltd.'s Annual General Meeting of Shareholders held on June 25, 2020. The filing details shareholder approvals regarding corporate governance, director elections, executive compensation, and insurance policies.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document notes that the Company's financial statements for the year ended December 31, 2019, were discussed at the meeting, but no numerical data from those statements is included in this report.
Material Changes
No material financial changes versus prior periods are reported in this filing. The document focuses on corporate actions approved by shareholders rather than financial performance updates.
Corporate Actions and Governance
- Auditor Approval: Shareholders ratified the appointment of Kesselman & Kesselman (PwC) as independent auditors for the fiscal year ending December 31, 2020.
- Director Elections:
- Re-elected Gerald Lieberman and Gerald M. Ostrov as Class III directors (term through 2023).
- Elected Sean Ellis as a Class III director (term through 2023).
- Elected Adam Gridley as a Class II director (term through 2022).
- Executive Compensation: Shareholders approved one-time grants or amended compensation terms for CEO Adam Gridley, President of R&D Dr. Phillip Schwartz, Chief Medical Officer Dr. Arthur Santora, and CFO Ms. Dana Yaacov-Garbeli.
- Insurance: Approved the purchase of a professional liability insurance policy for current and future directors and officers.
Key Facts for Investor Verification
- Verify the specific terms and amounts of the one-time compensation grants and amended agreements for the CEO, President of R&D, CMO, and CFO.
- Review the full Proxy Statement (Exhibit 99.1) referenced in the filing for detailed descriptions of the proposals.
- Confirm the Company's financial position by reviewing the audited financial statements for the year ended December 31, 2019, which are not included in this Form 6-K.